Should You Buy Roivant Sciences Ltd (ROIV) Today? Analysis, Price Targets, and 2026 Outlook.
Analysis Updated At
2026/01/26
Roivant Sciences Ltd. (ROIV) is not a strong buy at the moment for a beginner investor with a long-term focus. While the stock has positive analyst ratings and potential catalysts in its pipeline, the company's poor financial performance, lack of significant trading trends, and neutral technical indicators suggest that it is better to hold off on investing right now.
Technical Analysis
The stock's MACD is negative and expanding downward, indicating bearish momentum. RSI is neutral at 43.399, and the moving averages are bullish (SMA_5 > SMA_20 > SMA_200). The price is currently below the pivot level of 22.804, with key support at 21.91 and resistance at 23.698. Overall, the technical indicators suggest a neutral to slightly bearish trend.
Analyst Ratings and Price Target Trends
Analysts are overwhelmingly positive on the stock, with multiple firms raising price targets and maintaining Buy or Outperform ratings. The average price target is around $26-$28, suggesting upside potential from the current price of $22.53. However, these ratings are based on long-term catalysts, which may not align with the user's immediate investment goals.
Wall Street analysts forecast ROIV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ROIV is 27.63 USD with a low forecast of 22 USD and a high forecast of 33 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Wall Street analysts forecast ROIV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ROIV is 27.63 USD with a low forecast of 22 USD and a high forecast of 33 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Current: 21.910
Current: 21.910
